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Abstract
Background: Combination therapy with BRAF and MEK inhibitors significantly improves survival in BRAF mutated
melanoma patients but is unable to prevent disease recurrence due to the emergence of drug resistance. Cancer
stem cells (CSCs) have been involved in these long-term treatment failures. We previously reported in lung
cancer that CSCs maintenance is due to altered lipid metabolism and dependent upon Stearoyl-CoA-
desaturase (SCD1)-mediated upregulation of YAP and TAZ. On this ground, we investigated the role of SCD1
in melanoma CSCs.
Methods: SCD1 gene expression data of melanoma patients were downloaded from TCGA and correlated
with disease progression by bioinformatics analysis and confirmed on patient’s tissues by qRT-PCR and IHC
analyses. The effects of combination of BRAF/MEKi and the SCD1 inhibitor MF-438 were monitored by
spheroid-forming and proliferation assays on a panel of BRAF-mutated melanoma cell lines grown in 3D and
2D conditions, respectively. SCD1, YAP/TAZ and stemness markers were evaluated in melanoma cells and
tissues by qRT-PCR, WB and Immunofluorescence.
Results: We first observed that SCD1 expression increases during melanoma progression. BRAF-mutated
melanoma 3D cultures enriched for CSCs overexpressed SCD1 and were more resistant than 2D differentiated
cultures to BRAF and MEK inhibitors. We next showed that exposure of BRAF-mutated melanoma cells to
MAPK pathway inhibitors enhanced stemness features by upregulating the expression of YAP/TAZ and
downstream genes but surprisingly not SCD1. However, SCD1 pharmacological inhibition was able to
downregulate YAP/TAZ and to revert at the same time CSC enrichment and resistance to MAPK inhibitors.
Conclusions: Our data underscore the role of SCD1 as prognostic marker in melanoma and promote the use
of SCD1 inhibitors in combination with MAPK inhibitors for the control of drug resistance.
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Background
Over the past years, major breakthroughs have been
made in the medical treatment of melanoma. The advent
of molecular targeted agents and immune checkpoint
inhibitors consistently changed the treatment of patients
with advanced melanoma, leading to an unprecedented
improvement of survival outcomes [1, 2]. Randomized
phase III trials demonstrated that the BRAF inhibitors
namely vemurafenib and dabrafenib achieve an efficient
targeting of BRAF-mutated melanoma [3]. Given that
functional evidence pointed to continued activation of
the MAPK pathway as a way cancer cells exploit to
overcome the roadblock imposed by BRAF inhibitors,
combining BRAF and MEK inhibitors resulted in im-
proved clinical outcomes compared to single agent BRAF-
directed therapy [4–6]. Despite these therapeutic suc-
cesses, melanoma cells acquire the ability to withstand
combined BRAF and MEK inhibition. A number of
molecular mechanisms, eventually co-existing, have been
proposed in the attempt of explaining how melanoma
cells adapt to prolonged inhibition of BRAF and MEK.
Currently, evidence converge on the functional or muta-
tional reactivation of the MAPK pathway or, alternatively,
activation of parallel signalling avenues [7–11]. Adding
further complexity to this picture is the existence, within
the same tumour, of distinct cell clones relying on differ-
ent survival pathways.
A concept that acquired increased attention over the
past two decades is the existence of an uncommon
subpopulation of tumour cells with distinctive features,
defined as cancer stem cells (CSCs). This definition is
rooted into their ability to self-renew and capability to
propagate the tumour upon xenotransplantation in
immunocompromised mice [12–14].
The development of dedicated assays for functional
characterization of CSCs allowed to clarify two central
tenets of CSCs biology. First, the CSC state is not a fixed
condition, but rather a condition that can be acquired
when cells are exposed to specific stimuli deriving from
the microenvironment (e.g. hypoxia, low pH, epithelial-
mesenchymal transition, cytokines) [15–19].
Second, CSCs are intrinsically resistant to cytotoxic
therapies, such as chemotherapy and radiotherapy,
plausibly as result of their slow replication kinetics and
an extreme efficiency of the molecular machinery deputed
to repair genetic lesions [20, 21]. Indeed, while cytotoxic
agents eliminate more differentiated, quickly dividing
cells, the CSC pool expands in the attempt of replacing
dying tumour cells. On this ground, an efficient targeting
of CSCs has been advocated as essential for obtaining
long-lasting tumour remission. When considering tar-
geted agents, CSCs seem to be only marginally sensitive to
some therapeutics, while being vulnerable to the abroga-
tion of other signalling avenues that are instrumental for
their survival [22–24]. Recently, we and others have
reported that CSCs maintenance is due to an altered
metabolic status, characterized by a larger pool of mono-
unsaturated fatty acids (MUFAs), generated by the activity
of the Stearoyl-CoA desaturase 1 (SCD1) [25–32]. In pre-
vious studies, we demonstrated that SCD1 is a key factor
for lung CSCs, and that its inhibition selectively kills CSCs
acting synergistically with chemotherapy [25–28, 32].
Further corroborating this notion, a wave of studies dem-
onstrated that SCD1 confers malignant traits in arrays of
experimental models, spanning from ovarian and thyroid
cancers to endometrial and lung carcinomas [30, 32–35].
Remarkably, SCD1 is molecularly intertwined with canon-
ical pathways regulating the CSC pool, such as the Hippo
transducers YAP/TAZ, Wnt and Nf-Kb [30, 32–35]. Even
though SCD1 and, to a broader extent, lipid metabolism is
emerging as a central enzymatic node in controlling CSC
fate, evidence is still lacking on the connection between
SCD1 and resistance to pharmacological inhibition of the
MAPK pathway in melanoma.
Herein we analysed the correlation between SCD1
expression and melanoma progression, documenting the
nexus between SCD1 and tumour aggressiveness. This
prompted us to hypothesize that SCD1 may also be in-
volved in drug resistance. On this ground, we investi-
gated the consequences of targeting BRAF and MEK,
alone or in combination, in 3D and 2D in vitro models
of melanoma. With this approach, we observed that mel-
anoma CSCs are able to endure targeted agents, and that
this process is tied to an increased activity of SCD1.
Consistently, pharmacological inhibition of SCD1 effi-
ciently targeted melanoma CSCs and attenuated YAP/
TAZ activity, partly reverting their resistance to BRAF
and MEK inhibitors.
Methods
Reagents and plasmids
2-methyl-5-(6-(4-(2-(trifluoromethyl)phenoxy)piperidin-
1-yl)pyridazin-3-yl)-1,3,4-thiadiazole (MF-438) was
kindly provided by Ziga Jakopin. Vemurafenib (BRAF in-
hibitor) and Binimetinib (alias MEK162, MEK inhibitor)
were obtained from Selleck Chemicals. Chloroform
(CHCl3), methanol (CH3OH), hexane, isopropanol, and
bis(trimethylsilyl)-trifluoacetamide (TMS) were of MS
grade and were purchased from Merck (Darmstadt,
Germany). Butylated hydroxytoluene (BHT), K2SO4,
and HCl were purchased from Sigma–Aldrich, (Buchs,
Switzerland). Complementary DNA for human SCD1
was cloned into pCDNA3 as described in Noto et al.
[26].
Cell cultures
Established human melanoma cancer cells A375, M14,
WM115, LOXIMVI, WM266 and M14-R were obtained
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as previously described [36]. Cells in adherent condition
were cultured in RPMI-1640 (Sigma, St. Louis, MO,
USA) supplemented with 10% FBS (Sigma, St. Louis,
MO, USA) at 37 °C in an atmosphere of humidified air
with 5% CO2.
Primary cancer cell lines Mel 26, Mel 29, Mel 35, Mel
66, Mel 67 and normal melanocytes #1, #2, #3, #4 were
obtained from patients as described in Kovacs et al. [37].
Briefly melanoma cells were isolated from specimens
obtained from patients enrolled by the Melanoma Unit
of the San Gallicano Dermatologic Institute, Istituti
Fisioterapici Ospitalieri (IFO) after patients gave written
informed consent. Institutional Research Ethics Commit-
tee (IFO), approval was obtained to collect samples of
human material for research. The tissue was manually
crumbled in small pieces and then incubated with colla-
genase 0.35% for 45 min at 37 °C, centrifuged, resus-
pended and grown in OptiMEM (Life Technologies,
Invitrogen, Milan, Italy) medium containing 10% fetal
bovine serum and antibiotics. To maintain the integrity
of collections, all the primary cell lines were maintained
in culture no more than passages 2-12th. All cells were
routinely checked for mycoplasma contamination and
analysed for morphology.
Sphere formation
Sphere propagation assays were performed as previously
described [27, 38]. Briefly, single-cell preparation (1000
cells/well) of stable and primary cell lines were sus-
pended in an appropriate amount of sphere-forming
medium (serum-free DMEM/F12 supplemented with
bEGF, EGF, insulin, glucose, heparin, (Sigma, St. Louis,
MO, USA), B27 (Gibco, Invitrogen, Carlsbad, CA,
USA)), and plated into a 96-well ultra-low adherent plate
(Costar, USA) to form spheres. The documentation of
images and evaluation of sphere-forming efficiency were
performed on 4 days, or 7 days, as specified.
An average of 8–10 fields were used for these mea-
surements. Sphere-forming efficiency (%) was deter-
mined by dividing the number of spheres formed by the
original number of seeded cells. The quotient was then
multiplied by 100.
Drug treatments
The determination of IC50 was performed as previously
described [28]. Briefly, a dilution series of 3-fold incre-
ments of BRAFi/MEKi (0.007–20 μM) or MF-438
(0.007–50 μM), were prepared in sphere medium (or in
RPMI-1640 for clonogenic and for 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay).
Melanoma cells at a density of 1000/well in 96-well
plates were incubated in media with or without the
addition of BRAFi, MEKi and MF-438, administered either
alone or in combination for 7 days. The dose–response
curves were defined with KaleidaGraph software. Three in-
dependent experiments in duplicate were performed.
For other experiments, M14, M14-R, A375, Mel 29
and Mel 66 cell lines were seeded in the presence or
absence of BRAFi/MEKi (10 μM for M14 and M14-R;
1 μM for A375, Mel 29 and Mel 66) or MF-438 (1 μM).
After 96 h of drugs exposure, cells were washed with
Phosphate Buffered Saline (PBS) (Sigma, St. Louis, MO,
USA) and harvested for mRNA isolation, WB and IF
analyses. The size of spheroids was evaluated as de-
scribed in Pisanu et al. 2017.
Quantitative real-time PCR (qRT-PCR) analyses
For qRT-PCR total RNA was isolated with Trizol
Reagent (Life Technologies, Gaithersburg, MD, USA)
according to the manufacture’s guidelines. RNA was
digested with DNAase I (Invitrogen, Carlsbad, CA, USA)
and reverse-transcribed into cDNA using High Capacity
RNA-to cDNA Kit (Applied Biosystems, Life Technologies,
Gaithersburg, MD, USA). Quantitative RT-PCR was per-
formed using SYBR green detection (Applied Biosystem,
Life Technologies, Gaithersburg, MD, USA) and the ΔΔCt
method for relative quantification. Expression of β-actin
was used as internal control.
The primers used for individual genes are listen in
Additional file 1: Table S1.
Western blot analyses
Protein expression assays were performed as described
in Fattore et al. 2015 [39]. Briefly, cells were lysated in
RIPA buffer (Sigma, St. Louis, MO, USA) containing the
protease inhibitor cocktail (Hoffman-La Roche Ltd) for
total lysate or using NE-PER Nuclear Cytoplasmic
Extraction Reagent kit (Pierce, Rockford, IL, USA) to
separate nuclear fraction from cytosol and the protein
lysates were separated on SDS/PAGE acrylamide gel and
transferred on Polyvinylidenedifluoride (PVDF) mem-
branes. Membranes were blotted with different anti-
bodies and developed with ECL western blotting
substrate (GE Healthcare Life Sciences Marlborough,
MA, USA). The primary antibodies used were the fol-
lowing: anti-GAPDH, anti-tubulin, anti-vinculin (Sigma,
St. Louis, MO, USA), anti-SCD1 (Abcam, UK), anti-
pAKT, anti-AKT, anti-pERK, anti-ERK (Cell Signaling
Technology, Beverly, MA, USA), anti-YAP/TAZ and
anti-Laminin A/C (Santa Cruz Biotechnologies, Dallas,
Texas, USA). All results (mean ± SD of three independ-
ent experiments) were normalized over GAPDH, vincu-
lin or tubulin, as specified, and expressed as fold change
relative to density of control protein levels.
Immunofluorescence analyses and optical microscopy
For immunofluorescence analyses cells were fixed with 4%
paraformaldehyde (PFA; Sigma-Aldrich), permeabilized in
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0.1% Triton-X100 (Sigma-Aldrich, Milan, Italy), after
washing two times with PBS the cells were stained with
anti-SCD1, anti-JARID1B (Abcam, UK) and anti-YAP/
TAZ (Santa Cruz Biotechnologies, Dallas, Texas, USA)
antibody (1:50 dilution) or PBS alone as negative control
and incubated at 4 °C overnight. Next day, cells were
washed by PBS three times to remove unbound anti-
bodies, then secondary antibody (1:300 dilution) was
added in the dark and incubated at room temperature for
1 h. Then cells were stained with Hoechest 33,342 (1:1000
dilution) for 5min in the dark. Immunofluorescence
images and morphology observations of cell lines were
performed on Axiocam Camera (Zeiss) digital camera
coupled with Zeiss Axiovert optical microscope at 100x
and 320x magnification and analyzed using ZEN core soft-
ware (Zeiss). At least 8–10 fields were randomly captured
from each sample.
Transfections
-Plasmid Transfections. SCD1 DNA transfection was
performed with Lipofectamine 2000 (Thermofisher) ac-
cording to the manufacturer’s instructions. All of the
transfection experiments were performed with 500 ng of
each plasmid.
-siRNA transfection. We transfected small interfering
RNA-targeting SCD-1 (Sigma) or Scramble siRNA
(Sigma) into adherent cells using Lipofectamine RNAi
MAX Reagents (Invitrogen), according to the manufac-
turer’s recommendation. After 24 h from transfection,
cultures were grown in sphere medium and allowed to
form spheroids in presence or not of BRAFi and MEKi.
Lipid extraction
Lipids were extracted from A375 and M14 cells with a
method adapted from the Folch’s procedure [40]. Briefly,
about 2 × 106 cells were suspended in 300 μL of MilliQ
water (18.2Ω) and cracked by repeated freezing in liquid
nitrogen and-thawing. Cell debris were pelleted by spin-
ning at 11000 rpm for 5 min. Protein content was deter-
mined by Bradford assay in 5 μL supernatant. The pellet
was suspended by vortex-shaking and spiked with ten
nmoles of each d6-cholesterol and d98-TG 48:0 as the
internal standards (ISTD) to control recovery of lipids,
retention time (RT), and to calculate the amounts of
cholesterol and fatty acid methyl esters (FAME), respect-
ively. The ISTD mixture contained 0.001% of BHT to
prevent lipids autoxidation during processing. Liquid-li-
quid extraction of lipids was performed with 1 mL of
CHCl3/CH3OH 2:1 mixture. The bottom organic phase
was transferred to a clean glass tube. The operation was
repeated twice and the pooled organic phases were
evaporated to dryness under a nitrogen stream. The
dried lipid extract was dissolved in 400 μL CHCl3/
CH3OH 2:1 mixture and used for the analysis of the
profile of FAME.
FAME derivatization
To profile FA mostly bound in glycerol lipids and phos-
phoglycerol lipids, 90 μL of crude organic extract were
evaporated to dryness and then dissolved in 300 μL of
500 mM KOH in anhydrous CH3OH. To favor the
saponification and methylation of bound FA the mixture
was incubated at 37 °C under constant shaking for 20
min. To terminate reaction and neutralize the alkaline
mixture, 300 μL of 250 mM HCl were added. After vor-
tex mixing, 300 μL K2SO4 (6.7%) and 1mL hexane:iso-
propanol (3:2 v/v) mixture containing 0.0025% BHT
were added and vortexed vigorously. After centrifuga-
tion, the lipid enriched upper phase was transferred to
an Eppendorf tube and evaporated under nitrogen. The
reaction yielded FAME that were separated and detected
as described below to establish profiles of bound FA in
the lipid extracts.
Gas chromatography-mass spectrometry
Gas-chromatography coupled to mass spectrometry
(GC-MS) was used to quantitate FAME. The dried
FAME extract was dissolved in 180 μL of n-hexane. One
μL was injected onto the GC-MS equipment (Thermo-
Finnigan, Waltham, MA, USA). The chromatographic
separation was carried out on a HP-FFAP (crosslinked
FFAP, Agilent Technologies, Santa Clara, CA, USA) ca-
pillary column (length 50m, film thickness 0.52 μm).
Helium was used as the carrier gas. The initial GC oven
temperature was 40 °C and was linearly ramped at 8 °C/
min up to 240 °C. The total run time was 60 min. The
injector and the GC-MS transfer line were kept at 230 °
C and 250 °C, respectively. Total ion chromatograms
(TIC) were acquired, and areas of single peaks, corre-
sponding to individual FAME, were integrated with the
qualitative analysis software. Identity of the detected
FAME was verified by comparison with authentic stan-
dards and matched with library spectral data. The nmole
amounts of FAME were calculated against the nmole of
d31-hexadecanoate methyl ester (d31-C16:0ME) yielded
from d98-TG 48:0.
Tissue samples
Total RNA was extracted from the FFPE samples from 3
normal skin with well-represented melanocytes along
the basal layer of epidermis, 10 melanocytic common
nevi, 3 dysplastic melanocytic nevi, 12 stage I/II melano-
mas, 11 stage III/IV melanomas, as described in Fattore
et al. [41] (see Additional file 2: Table S2).
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Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections of
archival human tissue samples from the San Gallicano
Dermatologic Institute, Istituti Fisioterapici Ospitalieri
(IFO) of Rome, Italy and from Istituto Cantonale di
Patologia of Locarno, Switzerland (12 melanocytic nevi,
12 stage I/II melanomas, 11 stage III/IV melanomas)
were obtained with informed and signed consent, and
stained with anti-SCD1 (clone CD.E10). In collaboration
with Ospedale Sant’Andrea “Sapienza University of
Rome” the immunohistochemical staining was assessed
by one pathologist. SCD1 score was determined by posi-
tive cell (perinuclear/cytoplasm localization) percentage
in tumour tissues. Original magnification X 200.
Bioinformatics analyses
Human lung data were extracted from the GEO data-
base by using Oncomine bioinformatics tool on Talantov
dataset [42]. The data represent the median of SCD1 ex-
pression. Survival curves were estimated with the
Kaplan-Meier product-limit method and compared by
log-rank test, accessing data from cBioPortal bioinfor-
matics tool [43, 44].
Statistical analyses
All experiments were performed in triplicate and values
were calculated as mean ± standard deviation (SD) or
expressed as a percentage of controls ± SD. SCD1
mRNA and protein expression in patients was described
by median value (used as cut-off ). Differences between
two groups were determined using Anova, two-tailed
Mann Whitney or Student’s t-test as specified. Statistical
significance was set at p < 0.05.
Results
SCD1 is potentially useful for discriminating healthy
tissue from melanoma
We first sought to determine the diagnostic relevance of
SCD1 by analysing RNA levels in melanoma patients.
Bioinformatics analyses performed from data extracted
from publicly available cancer gene expression dataset
(Talantov) [45] using the Oncomine tool (https://
www.oncomine.org) demonstrated that SCD1 expression
discriminates melanoma from non-tumoral samples
(fold change = 3.4, p < 0.001) (Additional file 3: Figure
S1a). Likewise, SCD1 levels were significantly higher in
melanoma than in melanoma precursor lesions (fold
change = 4.6, p < 0.001) (Fig. 1a). These findings were
confirmed in tissues from an independent set of patients
by qRT-PCR (Fig. 1b and Additional file 3: Figure S1b)
and in a set of four primary cell lines isolated from the
same patients by western blot analyses (Fig. 1c). Further-
more, IHC analyses performed on human tissues ob-
tained from melanocytic nevi and melanoma (stage I-IV)
showed that SCD1 expression levels increased in paral-
lel with disease progression (p < 0.016, Mann Whitney
U Test) (Fig. 1d and Additional file 3: Figure S1c). It is im-
portant to note that, while the Oncomine tool does not
provide information on BRAF status in the Talantov data-
set, samples analysed in Fig. 1b, c, d, Additional file 3: Fig-
ure S1b and Figure S1c were obtained from BRAF
mutated tumours.
Finally, we evaluated the relationship between SCD1
expression and overall survival interrogating the TCGA
cohort (http://www.cbioportal.org/). As illustrated in
Additional file 3: Figure S1d, elevated expression of
SCD1 was associated with shorter survival (Log rank
p = 0.006), regardless of BRAF mutational status.
Based on these data, SCD1 may be a novel prognostic
factor in melanoma. However, since BRAF mutated
melanomas are the only subset in which a target ther-
apy has been approved, we focused subsequent studies
in this subset.
Higher SCD1 expression correlates with increased
stemness and drug resistance
Having documented that SCD1 expression increases
with melanoma progression, we hypothesized that SCD1
may be associated with resistance to targeted agents di-
rected against BRAF and MEK. To verify this hypothesis,
we first tested the expression of SCD1 in stable melan-
oma cells lines with different sensitivity to vemurafenib
(A375 (IC50 value 0.002 μM), M14 (IC50 value
0.13 μM), M14-R (IC50 value 0.25 μM) and WM115
(IC50 value 2.59 μM)), previously evaluated by MTT
assay (Fig. 2a). Western blotting analyses revealed an
increase of SCD1 expression in vemurafenib-resistant
cells versus sensitive cells, and a similar pattern was
recorded at the mRNA level (Fig. 2b-c).
To confirm the supposed connection between SCD1
and resistance to BRAF inhibition, we compared SCD1
expression in four stable resistant cell lines obtained
(described in the materials and methods section) and
their sensitive counterparts. With this approach, we
observed a 2-fold increase in SCD1 levels in resistant
cells, thus suggesting that SCD1 sustains resistance to
BRAF inhibition (Fig. 2d).
To further corroborate the involvement of SCD1 in
reducing the effectiveness of drugs directed against
BRAF and MEK we selected the most sensitive cell line
to vemurafenib (A375) expressing SCD1 at lower level
and verified the sensitivity to BRAF/MEK inhibitors
combination after enforced expression of SCD1 (Fig. 2e-g).
Interestingly, we observed that while the BRAF/MEK
inhibitors combination (50 nM, 1:1) was able to strongly
decrease pERK levels, ectopic expression of SCD1 restored
pERK levels (Fig. 2f) and mitigated inhibition of cell
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proliferation (Fig. 2g) thus suggesting that SCD1 activity
may promote drug resistance.
On this basis and considering our previous results that
delineated the role of SCD1 in: i) maintaining the CSC
compartment in lung cancer [27], and ii) inducing
chemotherapy-resistant features [28], we hypothesized that
lipid metabolic reprogramming may be also a distinctive
feature of melanoma CSCs, and that this phenomenon
installs therapeutic resistance.
Based on their ability to grow as 3D spheroids, we iso-
lated a highly tumorigenic cell subpopulation characterized
by an enrichment of markers associated with stemness such
as oct4, nanog, cd133, sox2 for A375, M14 and M14-R
stable and Mel 66, 29, primary BRAF-mutated cells lines
(Fig. 2h). This stem-like phenotype in 3D (Fig. 2i) was
consistent with an up-regulation of SCD1, both at the
transcript (Fig. 2j) and protein expression (Fig. 2k), and
with enhanced SCD1 activity evaluated by fatty acid methy-
lesters (FAME) profile by GS/MS. Indeed, 3D cultures
exhibited an increased fraction of unsaturated fatty acids
compared to 2D cultures in two stable cells analysed
(p ≤ 0.001) (Fig. 2l).
Fig. 1 SCD1 is potentially useful for discriminating healthy tissue from melanoma. a) Geo Skin Cutaneous Melanoma Talantov dataset was
analyzed for the expression of SCD1 by using Oncomine tool. Boxplot: cutaneous melanoma (n = 45); melanoma precursor (n = 18); b) mRNA
expression of SCD1 was determined by qRT-PCR analyses in melanoma patients affected by different tumor stage. The samples are grouped for
SCD1 gene by stage in melanoma precursor (n = 10) and cutaneous melanoma at different stage (n = 16); c) Western blotting analysis of SCD1
protein in four primary cell lines isolated from patients affected by cutaneous melanoma at different stage (upper panel) and four cell lines
obtained from non tumoral tissue (bottom panel). Mel 26 stage IB; Mel 35 stage IIC; Mel 66 IIC and Mel 29 stage IIIC. On the right boxplots
represent the quantification of SCD1 levels expressed as median value (fold-change = 1.9, p = 0.01); d) Representative images showing cellular
variability for IHC staining of SCD1 protein in melanoma patients. Magnification 200X (upper) 400X (bottom)
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Fig. 2 (See legend on next page.)
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Collectively these results indicate that an increased ex-
pression and activity of SCD1 in the CSC subpopulation
may be involved in therapeutic resistance to targeted
therapy in melanoma.
SCD1 expression is able to predict the response of BRAF-
mutated-melanoma cells to targeted agents
Given that the clinical role of the MAPKi is widely
documented in melanoma, we first tested whether BRAF
and MEK inhibitors possess a differential antitumor
activity between CSCs and their more differentiated
counterparts. Thus, different doses (0–20 μM) of vemur-
afenib and binimetinib were administered either alone
or in combination, in M14 and A375 stable cell lines
and in Mel 29 and Mel 66 primary melanoma cell lines
growing under 3D and 2D conditions. As illustrated in
the dose-response curves presented in Fig. 3a, single and
combination therapy were significantly more efficient
against cells growing in 2D cultures compared with
cells cultured under 3D conditions (see IC50 inserted
in Fig. 3a). This observation, coupled with evidence
that SCD1 expression levels are higher in 3D vs 2D
cultures, suggests that enhanced SCD1 expression
may be responsible for the therapy-resistant pheno-
type of melanospheres.
Remarkably, we found that BRAF and MEK inhibitors,
as well as their combination, resulted in an increased
compactness and size of spheroids (Fig. 3b-c).
Given that this finding suggested a paradox effect of
vemurafenib and binimetinib, namely a potential en-
richments of CSCs, we further verified drug-induced
increase of melanoma CSCs content by analysing
JARID1B (a member of the histone 3 K4 demethylase
family), which is an established marker of melanoma
CSCs [46, 47].
Immunofluorescence and qRT-PCR analyses consist-
ently documented a marked increase of JARID1B in
treated cells (Fig. 3d-e, P ≤ 0.02), along with an increased
percentage of JARID1B positive cells (Fig. 3f ) and
overexpression of a set of CSCs markers (nanog, oct4,
sox2 and cd133) (Fig. 3g, P ≤ 0.02).
As functional evidence pointed to AKT and ERK
hyper-activation as a strategy melanoma cells evolve to
tolerate prolonged BRAF and MEK inhibition [48, 49],
we evaluated total and activated (phosphorylated) forms
of AKT and ERK (pAKT and pERK) in untreated and
treated spheroids. Western blot analysis did not reveal
any clear increase of these proteins under treatment
(Fig. 4a). Likewise 3D-cultured cells did not show
increased levels of pAKT and pERK compared with their
counterparts growing in adhesion (Fig. 4b). Conse-
quently, intrinsic resistance of CSCs to targeted agents
seems to be independent from AKT and ERK activation,
but rather sustained by SCD1 activity. These findings in-
dicate that while BRAF and MEK inhibitors efficiently
eliminate more differentiated melanoma cells, they are
ineffective against melanoma CSCs and expand the
CSCs pool, in a process that is unrelated to the activa-
tion of effectors acting downstream or laterally the
MAPK pathway.
Once having excluded the involvement of some
established mechanisms of drug resistance in our cellu-
lar models, we verified whether the drug-resistant
phenotype was related to SCD1. Nevertheless, immuno-
fluorescence and western blotting did not reveal any
significant changes in SCD1 expression and in MUFA
levels in melanoma cell lines growing as spheroids
treated with vemurafenib, binimetinib or both agents
versus untreated cells (Fig. 4c-d and data not shown).
Reasoning that SCD1-mediated drug resistance at the
CSC level may be related to the control it operates on
established stemness-associated molecular signalling, we
specifically investigated the Hippo transducers YAP/TAZ
in our models. Indeed, experimental evidence points to
SCD1 as an emerging controller of YAP/TAZ activity
that, in turn, installs CSC traits [26]. We observed an
activation of YAP/TAZ in melanoma CSCs treated with
BRAF and/or MEK inhibitors, as documented by an
(See figure on previous page.)
Fig. 2 Higher SCD1 expression correlates with increased stemness and drug resistance. a) Evaluation of proliferation performed on A375, M14,
M14-R, WM115 by MTT assay after 72 h of vemurafenib exposure; b) MITF and SCD1 protein expression examined in BRAF-mutated melanoma
stable cell lines (A375, M14, M14-R, WM115) grown in adhesion by WB; c) qRT-PCR analyses performed on A375, M14, M14-R and WM115 in basal
condition; d) Western blotting analysis of SCD1 in A375, LOXIMV1, M14 and WM266 sensitive and their counterpart resistant to vemurafenib; e-f)
Western blotting performed on A375 transfected with empty or SCD1 vector in adherent conditions and treated or not with MAPKi combination
(50 + 50 nM) for 48 h. Densitometric analyses relative to SCD1, pERK and YAP/TAZ protein levels were expressed as a fold-change relative to
empty (CTRL); g) Evaluation of BRAFi/MEKi effects on proliferation performed on 2D A375-transfected with empty or SCD1 vector and treated for
72 h. The dose–effect curves shows a decreased sensitivity of A375 SCD1-overpressing compared to this of A375-transfected with empty vector;
h) Stemness gene expression in stable (left panel) and primary (right panel) cell lines by qRT-PCR; i) Representative images of melanoma cell lines
grown in 2D and 3D condition taken on day 4. Scale bars: 50 μM (3D) and 100 μM (2D); j) Gene expression of SCD1 performed on 3D and 2D
cultures by qRT-PCR analyses. The results indicate an enrichment of SCD1 mRNA expression in 3D spheroids compared with 2D parental cells; k)
Western blotting analysis of SCD1 protein in a large panel of melanoma stable and primary cell lines grown in 3D and 2D conditions; l) MUFA
levels in A375 and M14 cell lines analysed by GS/MS in 2D and 3D cultures. Data represent the means and SD of 3 independent experiments and
are statistically significant if *p < 0.05 (ANOVA test)
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increase of YAP/TAZ at the protein level in stable and
primary cell lines (M14, Mel 66, Mel 29) (Fig. 4e-f ),
coupled with the increase of YAP/TAZ target genes such
as ctgf, birc5, cyr61 and tead4 (Fig. 4g). These findings
are consistent with a previous study suggesting YAP and
TAZ as BRAF inhibitors resistance factors [50].
Thus, treatment with MAPKi (both BRAF and/or
MEK inhibitors) enriches the CSC pool, through a
process that requires SCD1-mediated increased tran-
scriptional activity of YAP/TAZ.
This suggests that melanoma cells with high levels of
SCD1 may be insensitive to MAPKi treatment and that
SCD1 could discriminate BRAF-mutated melanoma into
MAPK-sensitive and -resistant subpopulations.
SCD1 inhibition efficiently targets melanoma stem cells
and reverted their resistance to BRAF and MEK inhibitors
We have previously reported on the ability of MF-438
to efficiently inhibit SCD1 function. To address the
anti-CSCs properties of MF-438, 3D melanoma cell
cultures were exposed to MF-438 given as single-
agent or in combination with vemurafenib and bini-
metinib. Consistent with the preferential activation of
SCD1 in the CSCs pool, its inhibition in M14 and
A375 decreased MUFA levels (Fig. 5a), hindered
sphere-forming efficiency when given as single treat-
ment (Fig. 5b), and overcame the intrinsic resistance
of spheroids to BRAF and MEK inhibitors (Fig. 5c).
Next, we compared the antitumor activity of MF-438
in 3D cultures versus their differentiated counterparts.
Figure 5d shows that treatment with MF-438 reduced
cell viability of CSCs, while resulting largely ineffect-
ive against non-CSCs. These lethal effects were ac-
companied by decreased expression levels of the stem
cell markers oct4, nanog and jarid1b (Fig. 5e).
Moreover, we observed that the triple targeting of
BRAF-MEK-SCD1 in resistant spheroids reduced YAP/
TAZ protein levels, their nuclear accumulation and
expression of YAP/TAZ target genes (Fig. 5f-h). To
confirm that the observed biological effects on melan-
oma CSCs are related to selective SCD1 targeting we si-
lenced SCD1 and, after checking the silencing efficiency
(Fig. 6a) we analysed the mRNA expression levels of the
stem cell markers nanog, cd133, jarid1b and oct4. Con-
sistently with our hypothesis, a decrease in their levels
was observed (Fig. 6b). Importantly, SCD1 silencing led
to a downregulation of YAP/TAZ expression at the pro-
tein level mostly in BRAF/MEKi-treated spheroids (Fig.
6c). Moreover, mRNA levels of birc5 and tead4 genes
which were increased after BRAF/MEK inhibitor treat-
ment, decreased upon SCD1 silencing (Fig. 6d).
Finally, to better understand the mechanisms behind
changes in YAP/TAZ activity following drug treatments
we also determined changes in YAP/TAZ cellular distri-
bution upon MAPKi treatment, SCD1 inhibition by
RNA silencing and pharmacological treatments or their
combinations. This was carried out by analysing their
expression levels in the cytosolic and nuclear compart-
ment respectively (Fig. 6e). Overall, we observed that
MAPKi exposure induced a slight increase of YAP nu-
clear localization accompanied by a parallel decrease in
the cytosol fraction. In contrast SCD1 inhibition reduced
YAP levels both in the nucleus and in the cytosol.
Collectively, our findings confirmed that SCD1 activa-
tion denotes a metabolic route preferentially activated in
melanoma CSCs, and that its abrogation preferentially
killed this subpopulation.
Overall, our data support the role of SCD1 as a prom-
ising therapeutic target in combination with MAPKi in
BRAF mutated melanoma and suggest a possible func-
tion as diagnostic and prognostic marker.
Discussion
The advent of molecular targeted agents dramatically
changed the treatment landscape of advanced melan-
oma. Nevertheless, melanoma cells adapt to the block
of BRAF and MEK, becoming able to thrive even
under pharmacological pressure. Thus, achieving a
(See figure on previous page.)
Fig. 3 SCD1 expression is able to predict the response of BRAF-mutated-melanoma cells to targeted agents. a) Single-cell suspensions of
melanoma cell lines were seeded onto a 96-plate ultra low attachment in sphere medium (3D) or in 96-plate cultured in RPMI-1640 (2D). Cell
cultures treated with increasing concentrations of BRAF inhibitor (BRAFi) or MEK inhibitor (MEKi) (0.07–20 μM) alone or in simultaneous
combination. After 7 days of treatment the sphere-forming efficiency (%) of 3D cancer cells was compared to untreated cells. In parallel the
proliferation (%) of 2D cancer cells was compared to control (CTRL). Inset shows the evaluation of drug effects (IC50 value in 3D (red) and in 2D
(blu)) performed on melanoma cell lines by Calcusyn software; b) Representative images of sphere formation of first generation taken on day 4.
Scale bars: 50 μm. Single-cell suspensions of M14, A375, Mel 66 and M14-R cell lines were seeded in sphere medium and simultaneously treated
with BRAF and MEK inhibitors alone or in combination for 4 days; c) Morphometric analysis of spheroids from treated or untreated M14 and
A375. The median value plotted in boxplots showed that treated cultures were characterized by a higher size of spheroids compared to the
untreated cultures; d) Immunofluorescence analyses on JARID1B expression were performed on M14, A375 and M14-R spheroids after 96 h of
exposure to BRAF or MEK inhibitors and their combination; Scale bars: 50 μm; e) mRNA expression of jarid1b was determined by qRT-PCR after 96
h of drugs exposure. Jarid1b results upregulated by BRAF/MEK inhibitors on M14 and a375 cell lines. All data represent the means and SD of 3
independent experiments and are statistically significant if p < 0.05 (Anova test); f) Percentage of JARID1B positive cells treated with BRAF and
MEK inhibitors and their combination; g) Stemness markers analysed on M14 and A375 cell lines after BRAF plus MEK inhibitors by qRT-PCR
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deeper understanding of the forces feeding thera-
peutic resistance to current pathway-focused inhibi-
tors is of utmost importance. In the present study, we
investigated how melanospheres react when exposed
to routinely used molecularly targeted agents, namely the
BRAF inhibitor vemurafenib and MEK inhibitor binimeti-
nib. Overall, our findings indicate that: i) BRAF and MEK
inhibitors are unable to eliminate MSCs, which however
Fig. 4 SCD1 expression is able to predict the response of BRAF-mutated-melanoma cells to targeted agents. a-b) AKT and ERK pathways were
examined by WB analyses in protein lysates prepared from M14, A375 and M14-R cells treated with BRAF and MEK inhibitors or their combination
(panel a) grown in adhesion (2D) and as spheroids (3D) (panel b); c) SCD1 protein expression performed on fixed M14, A375 and M14-R
spheroids after 96 h of treatment with BRAF and/or MEK inhibitors by Immunofluorescence analyses. Scale bar 50 μm; d) WB analysis of SCD1
protein expression performed on M14-R and M14 spheroids after 96 h of BRAF and/or MEK inhibitors exposure; e) Immunofluorescence analyses
on YAP/TAZ expression were performed on fixed M14, Mel 29 and Mel 66 spheroids after 96 h of exposure to BRAF/MEK inhibitors; Scale bars:
10 μm; f) Western blotting analysis of YAP/TAZ in M14, Mel 29 and Mel 66 spheroids after BRAF/MEK inhibitors exposure; g) YAP/TAZ downstream
target ctgf, cyr61, birc5 and tead4 expression in A375, M14, Mel 29 and Mel 66 by qRT-PCR analyses
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do not rely on AKT and/or ERK activation to endure
vemurafenib- and binimetinib-induced death stimuli, ii)
increased activity of SCD1, the rate-limiting enzyme in the
formation of monounsaturated fatty acids, enables
melanoma CSCs to survive BRAF and MEK inhibition, iii)
this process is related to the control SCD1 operates on
YAP/TAZ, and iv) pharmacological inhibition of SCD1,
achieved with MF-438, selectively killed melanoma CSCs
and partly restored sensitivity to the combination of
vemurafenib and trametinib. To our knowledge, this is the
first report describing the involvement of lipid metabolism
in sustaining therapeutic resistance in melanoma CSCs.
Moreover, data herein presented open up a novel thera-
peutic scenario, envisioning the inhibition of specific
metabolic routes to erase melanoma-initiating cells. More-
over, SCD1 inhibition was found to selectively target can-
cer cells, while sparing non-transformed cells. This is of
great relevance for therapeutic purposes, as the potential
activity of SCD1 inhibition might not be counterbalanced
by excessive side effects.
Metabolic reprogramming is considered a hallmark of
cancer. Metabolic changes occurring upon malignant
transformation are instrumental to cope with genetically
deregulated proliferative signalling, and to withstand
hostile environmental conditions such as hypoxia and
low availability of nutrients. While glucose and glutam-
ine pathway alterations have been recognized as central
metabolic changes since the earliest biochemical studies,
the contribution of lipids and cholesterol pathways is
still underestimated. Nevertheless, as evidence accumu-
late, lipid reprogramming is gaining popularity given
that alterations in lipid composition (e.g. content of
saturated versus unsaturated fatty acids) is intimately
tied to protein dynamics and membrane fluidity. In
particular, monounsaturated fatty acids, derived from
saturated fatty acids by the action of SCDs, have been
associated with the acquisition of malignant features
[51, 52]. However, how lipid metabolism is concatenated
with CSC fate remains un understudied domain of
stem cell biology [53]. Indeed, since the discovery of
CSCs two decades ago, characterization efforts have
mostly been oriented toward blocking the so-called
stem cell pathways (e.g. Notch, Hedgehog, TGF-β),
and to interfere with the molecular network deputed
to protect their genome in the attempt of reverting
chemo-resistance [54]. Even though the study of lipid
metabolism in CSC is still in its infancy, recent stud-
ies are beginning to shed light on a novel regulatory
force [55]. Parallel with the appreciation of metabolic
avenues that operate in CSCs, the inhibition of
specific metabolic functions has been proposed for
therapeutic purposes. For instance, activation of the
mevalonate pathway, which is responsible for the syn-
thesis of cholesterol, has been found to endow breast
cancer cells with stem cell traits [56]. Consistently,
the targeting of HMG-CoA reductase, the rate-limit-
ing enzyme of the mevalonate cascade, achieved with
cholesterol-lowering agents (statins), resulted effective
against breast cancer stem cells. Regarding SCD1,
previous studies pointed to SCD1 activity as a novel
player involved in maintaining stemness in ovarian
and lung cancer cells [26–31]. Our study adds a fur-
ther piece to the puzzle, providing a nexus between
lipid alterations, stem cell pathway (YAP/TAZ) and
targeted therapy resistance at the CSC level. We envi-
sion that two major questions should deserve
increased attention in future studies attempting to
delineate the metabolic landscape of CSCs, and its
connection with therapeutic resistance. First, the
metabolic demand of CSCs plausibly varies in relation
to the switch from quiescence to proliferation and
vice versa, thus adding an element of dynamicity that
deserves tailored investigations. Second, the molecular
output of lipid reprogramming is still unclear. Even
though pioneering studies are beginning to connect
lipid metabolism to CSCs via intermediate molecular
cascades (e.g. the Hippo pathway), we foresee the
existence of a broader network of canonical signal
(See figure on previous page.)
Fig. 5 a) MUFA levels analysed by GS/MS in M14 and A375 BRAF/MEK plus MF438 treated cells; b) 12 Representative images of sphere formation
of first generation taken on day 4. Scale bars: 50 μm. 13 Single-cell suspensions of M14, A375 and Mel 66 cell lines were seeded at 1000/well
onto a 6-plate 14 ultra low attachment in sphere medium and treated with MF-438 alone or in combination with 15 BRAF/MEK inhibitors for 4
days; c) Sphere forming efficiency evaluated on A375, M14 and Mel 16 66 cell lines seeded at 1000/well onto a 96-plate ultra low attachment in
sphere medium (3D). Cell 17 cultures treated with increasing concentrations of BRAF and MEK inhibitors (0.07-20 μM) 18 combined or not with
MF-438 (0.07-50 μM). After 7 days of treatment the sphere-forming 19 efficiency of 3D cancer cells was compared to untreated cells; d)
Proliferation assay performed on 20 2D and 3D cultures obtained from A375 and M14 cell lines exposed to MF-438 for 7 days; inset 21 shows the
IC50 value calculated in 3D culture treated with BRAF/MEK and or BRAF/MEK plus 22 MF-438 (panel c) and IC50 3D vs 2D condition (panel d); e)
Stemness markers (oct4, nanog, 23 jarir1b) analysed on M14 and A375 melanoma cells after BRAF/MEK plus MF-438 inhibitors by 24 qRT-PCR; f)
Western blotting analysis of YAP/TAZ in M14 and Mel 66 spheroids treated with 25 BRAF, MEK or BRAF/MEK plus MF-438 for 96 hours; g)
Immunofluorescence analyses of YAP/TAZ after BRAF/MEK inhibitors plus MF-438 performed on M14 and Mel 66 cell lines. 2 Scale bar 10mm; h)
YAP/TAZ downstream target analysed after MF-438 combined with BRAF and 3 MEK inhibitors in A375, M14 and Mel 66
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transduction pathways whose activity, and consequent
impact on CSC properties, can be tuned by alter-
ations in lipid content.
Conclusions
In this study, we provide evidences that melanoma
CSCs are able to tolerate the pharmacological inhibition
of BRAF and MEK, a process sustained by the in-
creased function of SCD1. This, in turn, enhances
the transcriptional activity of the Hippo transducers
YAP/TAZ. Consistently, inhibition of SCD1 elicits
lethal effects and override the intrinsic resistance to
BRAF and MEK inhibitors that characterizes melan-
oma CSCs.
Fig. 6 SCD1 inhibition efficiently targets melanoma stem cells and reverted their resistance to MAPK inhibitors. a) Efficiency of silencing of
SCD1 analyzed by qRT-PCR performed on M14 cells grown in 2D for 96 h; b) Gene expression of nanog, cd133, jarid1b and oct4 after
SCD1 silencing in M14 spheroids determined by qRT-PCR; c) Representative western blotting analysis of total lysates obtained from M14
silenced and treated with BRAFi/MEKi showing SCD1 and YAP/YAZ protein expression; d) Gene expression analyses of YAP/TAZ gene
targets performed on M14 spheroids SCD1 silenced and treated with BRAFi/MEKi combination. The results confirmed that SCD1 inhibition
by silencing partially reverts the enrichment of YAP/TAZ gene targets induced by MAPKi exposure; e) Western blotting of nuclear and
cytosolic fractions obtained from M14 spheroids treated with BRAFi/MEKi in presence of SCD1 silencing (left panel) or simultaneously
treated with MF-438 (right panel). Densitometric analyses of western blotting showed as a fold-change vs relative CTRL
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Characteristics. (DOCX 47 kb)
Additional file 3 Figure S1. a) Geo Skin Cutaneous Melanoma dataset
was analyzed for the expression of SCD1 by using Oncomine tool. The
samples are grouped in normal (skin n = 7) and cutaneous melanoma
(45). The median value is statistically different (p < 0.001); b) SCD1 gene
expression by qRT-PCR in melanocytes (n = 3) vs cutaneous melanoma
(n = 21). The data represent the median value of log2ΔCt. The results
are significant (p < 0.001); c) Quantification of SCD1 expression in tissue
of melanocytic nevi (n = 12) and cutaneous melanoma (n = 21). SCD1
level expressed as median value was present at different expression
levels (> 70% at late stages, (> 10 - < 70% at intermediate stages, ≤ 10% at
early stages). Comparison of two groups by Mann Whitney U test resulted
statistically significant (p < 0.016); d) Kaplan-Meier curves indicating SCD1
mRNA expression analyzed by using cBioPortal tool. Red curve represents
patients group in which SCD1 gene is overexpressed, while blue curve
represents patients expressing low SCD1 content. (TIF 3558 kb)
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